@Article{,
AUTHOR = {Eric Winquist, John J. Wilson, Mark Dorreen, Ralph Wong, Derek Jonker, Neil Iscoe},
TITLE = {A3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {11},
YEAR = {2004},
NUMBER = {6},
PAGES = {2445--2449},
URL = {http://www.techscience.com/CJU/v11n6/62566},
ISSN = {1488-5581},
ABSTRACT = {<b>Objective:</b> To assess the efficacy and tolerability of a 3-week outpatient schedule of intravenous gemcitabine and cisplatin in patients with locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract (TCC).<br/>
<b>Patients and methods:</b> A two-stage phase II trial enrolled TCC patients with Karnofsky performance status >60, measurable disease, and adequate organ function. Prior adjunctive chemotherapy was allowed provided it had been completed at least 1 year prior to study entry. Treatment consisted of gemcitabine 1250 mg/m<sup>2</sup> iv days 1 and 8 plus cisplatin 70 mg/m<sup>2</sup> day 1 iv repeated every 21 days. The primary outcome was the objective response rate.<br/>
<b>Results:</b> Thirty patients were enrolled at six Canadian centres. Three complete and 10 partial responses were observed in 29 eligible patients (overall response rate 45% [95% CI, 27-63%]). Three patients had stable disease and 13 had progressive disease. The relative dose-intensities of gemcitabine and cisplatin were 81% and 88%, respectively. Toxicity was primarily hematological, and 60% of patients experienced at least one episode of grade 3 or 4 toxicity. One patient died of neutropenic sepsis and two died of vascular events while on treatment.<br/>
<b>Conclusions:</b> The efficacy and tolerability of this schedule are similar to that reported with the standard 4-week schedule of gemcitabine-cisplatin. In the absence of a large randomized trial, the similarity of these results supports the use of this 3-week program in typical TCC patients treated in both community and academic cancer clinic settings.},
DOI = {}
}